Inflammatory mechanisms of stroke

Stroke

Volumn 41, Issue 10 SUPPL. 1, 2010, Pages

  Elkind, Mitchell S V ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

atherosclerosis inflammation; cerebral thrombosis; infection; infectious burden; risk factors; statins; stroke

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; C REACTIVE PROTEIN; PLACEBO; ROSUVASTATIN;

ATHEROSCLEROSIS; CAROTID ATHEROSCLEROSIS; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; HUMAN; INFECTION; INFLAMMATION; INFLUENZA; INFLUENZA VACCINATION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; STROKE; THROMBOSIS; COMPLICATION; PATHOLOGY;

ATHEROSCLEROSIS; DISEASE PROGRESSION; HUMANS; INFLAMMATION; PROGNOSIS; RISK FACTORS; STROKE;

EID: 77957978930     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.594945     Document Type: Conference Paper

References (71)

1. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107: 499-511.
2. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
3. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731-733.
4. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843. (Pubitemid 30165206)
5. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347: 1557-1565.
6. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97:2007-2011.
7. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. J Am Med Assoc. 2007;297:611-619.
8. Cao JJ, Thach C, Manolio TA, Psaty BM, Kuller LH, Chaves PH, Polak JF, Sutton-Tyrrell K, Herrington DM, Price TR, Cushman M. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation. 2003;108: 166-170.
9. Gussekloo J, Schaap MC, Frolich M, Blauw GJ, Westendorp RG. C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. Arterioscler Thromb Vasc Biol. 2000;20:1047-1051
10. The Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375: 132-140.
11. Rost NS, Wolf PA, Kase CS, Kelly-Hayes M, Silbershatz H, Massaro JM, D'Agostino RB, Franzblau C, Wilson PW. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack. Stroke. 2001;32:2575-2579.
12. Curb JD, Abbott RD, Rodriguez BL, Sakkinen P, Popper JS, Yano K, Tracy RP. C-reactive protein and the future risk of thromboembolic stroke in healthy men. Circulation. 2003;107:2016-2020.
13. Elkind MS, Luna JM, Moon YP, Liu KM, Spitalnik S, Paik MC, Sacco RL. High-sensitivity C-reactive protein predicts mortality but not stroke: the Northern Manhattan Study. Neurology. 2009;73:1300-1307.
14. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Rubin SM, Ding J, Simonsick EM, Harris TB, Pahor M. Inflammatory markers and onset of cardiovascular events: results from the health ABC Study. Circulation. 2003;108:2317-2322.
15. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. J Am Med Assoc. 2005;293:1609-1616.
16. Wright CB, Moon YP, Paik MC, Brown TR, Rabbani LR, Yoshita M, DeCarli C, Sacco RL, Elkind MSV. Inflammatory biomarkers of vascular risk as correlates of leukoariosis. Stroke. 2009;40:3466-3471.
17. Everett BM, Glynn RJ, MacFadyen JG, Ridker PM. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER). Circulation. 2010;121:143-150.
18. Woodward M, Lowe GDO, Campbell DJ, Colman S, Rumley A, Chalmers J, Neal BC, Patel A, Jenkins AJ, Kemp BE, MacMahon SW. Associations of inflammatory and hemostatic variables with the risk of recurrent stroke. Stroke. 2005;36:2143-2147.
19. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL. Lipoprotein-associated phospholipase A2, C-reactive protein, and outcome after ischemic stroke. Arch Intern Med. 2006;166:2073-2080.
20. 2 stability before and after stroke and myocardial infarction. Stroke. 2009;40: 3233-3237.
21. Elkind MSV, Coates K, Tai W, Paik MC, Boden-Albala B, Sacco RL. Levels of acute phase proteins remain stable after ischemic stroke. BMC Neurol. 2006;6:37.
22. Di Napoli M, Schwaninger M, Cappelli R, Ceccarelli E, Di Gianfilippo G, Donati C, Emsley HC, Forconi S, Hopkins SJ, Masotti L, Muir KW, Paciucci A, Papa F, Roncacci S, Sander D, Sander K, Smith CJ, Stefanini A, Weber D. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: A statement for health care professionals from the CRP Pooling Project members. Stroke. 2005;36: 1316-1329.
23. Elkind MSV, Luna JM, Coffey CS, McClure LA, Liu KM, Spitalnik S, Paik MC, Roldan A, White C, Hart R, Benavente O. The Levels of Inflammatory Markers in the Treatment of Stroke (LIMITS) Study: inflammatory biomarkers as risk predictors after lacunar stroke. Int J Stroke. 2010;5:117-125.
24. Elkind MSV. Why now? moving from stroke risk factors to stroke triggers. Curr Opin Neurol. 2007;20:51-57.
25. Virok D, Kis Z, Karai L, Intzedy L, Burian K, Szabo A, Ivanyi B, Gonczol E. Chlamydia pneumoniae in atherosclerotic middle cerebral artery. Stroke. 2001;32:1973-1976.
26. Vink A, Poppen M, Schoneveld AH, Roholl PJM, de Kleijn DPV, Borst C, Pasterkamp G. Distribution of Chlamydia pneumoniae in the human arterial system and its relation to the local amount of atherosclerosis within the individual. Circulation. 2001;103:1613-1617.
27. Maass M, Bartels C, Engel PM, Mamat U, Sievers HH. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol. 1998;31:827-832. (Pubitemid 28186419)
28. Jackson LA, Campbell LA, Kuo CC, Rodriguez DI, Lee A, Grayston JT. Isolation of Chlamydia pneumoniae from a carotid artery specimen. J Infect Dis. 1997;176:292-295.
29. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet. 1997;350:430-436.
30. Kalayoglu MV, Libby P, Byrne GI. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. J Am Med Assoc. 2002; 288:2724-2731.
31. Elkind MS, Lin I-F, Grayston TJ, Sacco RL. Chlamydia pneumoniae and the risk of first ischemic stroke: the Northern Manhattan Stroke Study. Stroke. 2000;31:1521-1525.
32. Elkind MS, Sciacca R, Tondella MLC, Feikin D, Fields B, DiTullio MR. Antibodies to Chlamydia pneumoniae are associated with risk of ischemic stroke. Neurology. 2003;60(suppl 1):A256-A257.
33. Madre JG, Garcia JL, Gonzalez RC, Montero JM, Paniagua EB, Escribano JR, Martinez JD, Cenjor RF. Association between seroposi-tivity to Chlamydia pneumoniae and acute ischaemic stroke. Eur J Neurol. 2002;9:303-306.
34. Cook PJ, Honeybourne D, Lip GYH, Beevers DG, Wise R, Davies P. Chlamydia pneumoniae antibody titers are significantly associated with acute stroke and transient cerebral ischemia: the West Birmingham Stroke Project. Stroke. 1998;29:404-410.
35. Fagerberg B, Gnarpe J, Gnarpe H, Agewall S, Wikstrand J. Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease. Stroke. 1999;30: 299-305.
36. Glader CA, Stegmayr B, Boman J, Stenlund H, Weinehall L, Hallmans G, Dahlén GH. Chlamydia pneumoniae antibodies and high lipoprotein(a) levels do not predict ischemic cerebral infarctions. Stroke. 1999;30: 2013-2018.
37. Tanne D, Haim M, Boyko V, Goldbourt U, Reshef T, Adler Y, Brunner D, Mekori YA, Behar S. Prospective study of Chlamydia pneumoniae IgG and IgA seropositivity and risk of incident ischemic stroke. Cere-brovasc Dis. 2003;16:166-170.
38. Heuschmann PU, Neureiter D, Gesslein M, Craiovan B, Maass M, Faller G, Beck G, Neundoerfer B, Kolominsky-Rabas PL. Association between infection with Helicobacter pylori and Chlamydia pneumoniae and risk of ischemic stroke subtypes: results from a population-based case-control study. Stroke. 2001;32:2253-2258.
39. Fabricant CG, Fabricant J, Minick CR, Litrenta MM. Herpesvirus-induced atherosclerosis in chickens. Fed Proc. 1983;42:2476-2479.
40. Benditt EP, Barrett T, McDougall JK. Viruses in the etiology of atherosclerosis. Proc Natl Acad Sci U S A. 1983;80:6386-6389.
41. Ventura HO, Mehra MR, Smart FW, Stapleton DD. Cardiac allograft vasculopathy: current concepts. Am Heart J. 1995;129:791-798.
42. Melnick JL, Adam E, Debakey ME. Possible role of cytomegalovirus in atherogenesis. J Am Med Assoc. 1990;263:2204-2207.
43. Espinola-Klein C, Rupprecht HJ, Blankenberg S, Bickel C, Kopp H, Rippin G, Hafner G, Pfeifer U, Meyer J. Are morphological or functional changes in the carotid artery wall associated with Chlamydia pneumoniae, Helicobacter pylori, cytomegalovirus, or herpes simplex virus infection? Stroke. 2000;31:2127-2133.
44. Ridker PM, Hennekens CH, Stampfer MJ, Wang F. Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke. Circulation. 1998;98:2796-2799.
45. Espinola-Klein C, Rupprecht HJ, Blankenberg S, Bickel C, Kopp H, Rippin G, Victor A, Hafner G, Schlumberger W, Meyer J. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation. 2002;105:15-21. (Pubitemid 34049136)
46. Espinola-Klein C, Rupprecht HJ, Blankenberg S, Bickel C, Kopp H, Victor A, Hafner G, Prellwitz W, Schlumberger W, Meyer J. Impact of infectious burden on progression of carotid atherosclerosis. Stroke. 2002; 33:2581-2586. (Pubitemid 35266427)
47. Zhu J, Quyyumi AA, Norman JE, Csako G, Waclawiw MA, Shearer GM, Epstein SE. Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. Am J Cardiol. 2000;85:140-146.
48. Zhu J, Nieto FJ, Horne BD, Anderson JL, Muhlestein JB, Epstein SE. Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation. 2001;103:45-51.
49. Smieja M, Gnarpe J, Lonn E, Gnarpe H, Olsson G, Yi Q, Dzavik V, McQueen M, Yusuf S; Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 2003;107:251-257.
50. Dai DF, Lin JW, Kao JH, Hsu CN, Chiang FT, Lin JL, Chou YH, Hsu KL, Tseng CD, Tseng YZ, Hwang JJ. The effects of metabolic syndrome versus infectious burden on inflammation, severity of coronary atherosclerosis, and major adverse cardiovascular events. J Clin Endocrinol Metab. 2007;92:2532-2537.
51. Szklo M, Ding J, Tsai MY, Cushman M, Polak JF, Lima J, Barr RG, Sharrett AR. Individual pathogens, pathogen burden and markers of subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis. J Cardiovasc Med (Hagerstown). 2009;10:747-751.
52. Grau AJ, Preusch MR, Palm F, Lichy C, Becher H, Buggle F. Association of symptoms of chronic bronchitis and frequent flu-like illnesses with stroke. Stroke. 2009;40:3206-3210.
53. Elkind MSV, Ramakrishnan P, Moon YP, Boden-Albala B, Liu KM, Spitalnik SL, Rundek T, Sacco RL, Paik MC. Infectious burden and risk of stroke: the Northern Manhattan Study. Arch Neurol. 2010;67:33-38.
54. Elkind MSV, Luna JM, Moon YP, Boden-Albala B, Liu KM, Spitalnik S, Rundek T, Sacco RL, Paik MC. Infectious burden and carotid plaque thickness: the Northern Manhattan Study. Stroke. 2010;41:e117-e122.
55. Syrjanen J, Valtonen VV, Iivanainen M, Kaste M, Huttunen JK. Preceding infection as an important risk factor for ischaemic brain infarction in young and middle aged patients. BMJ. 1988;296:1156-1160.
56. Grau AJ, Buggle F, Heindl S, Steichen-Wiehn C, Banerjee T, Maiwald M, Rohlfs M, Suhr H, Fiehn W, Becher H. Recent infection as a risk factor for cerebrovascular ischemia. Stroke. 1995;26:373-379.
57. Bova IY, Bornstein NM, Korczyn AD. Acute infection as a risk factor for ischemic stroke. Stroke. 1996;27:2204-2206.
58. Grau AJ, Buggle F, Becher H, Zimmermann E, Spiel M, Fent T, Maiwald M, Werle E, Zorn M, Hengel H, Hacke W. Recent bacterial and viral infection is a risk factor for cerebrovascular ischemia. Neurology. 1998; 50:196-203.
59. Macko RF, Ameriso SF, Gruber A, Griffin JH, Fernandez JA, Barndt R, Quismorio FP Jr, Weiner JM, Fisher M. Impairment of the protein C system and fibrinolysis in infection-associated stroke. Stroke. 1996; 27:2005.
60. Elkind MS, Carty CL, O'Meara ES, Lumley T, Lefkowitz D, Kronmal RA, Longstreth WT. Hospitalizations for infections trigger acute ische-mic stroke: the Cardiovascular Health Study. Stroke. 2010;41:e25.
61. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351:2611-2618.
62. Grau AJ, Fischer B, Barth C, Ling P, Lichy C, Buggle F. Influenza vaccination is associated with a reduced risk of stroke. Stroke. 2005;36: 1501-1506.
63. Madjid M, Naghavi M, Litovsky S, Casscells SW. Influenza and cardiovascular disease: A new opportunity for prevention and the need for further studies. Circulation. 2003;108:2730-2736.
64. Naghavi M, Wyde P, Litovsky S, Madjid M, Akhtar A, Naguib S, Siadaty MS, Sanati S, Casscells W. Influenza infection exerts prominent inflammatory and thrombotic effects on the atherosclerotic plaques of apoli-poprotein E-deficient mice. Circulation. 2003;107:762-768.
65. Losurdo G, Giacchino R, Castagnola E, Gattorno M, Costabel S, Rossi A, Amato S, Di Pietro P, Molinari AC. Cerebrovascular disease and varicella in children. Brain Dev. 2006;28:366-370.
66. Advisory Committee on Immunization Practices; Smith NM, Bresee JS, Shay DK, Uyeki TM, Cox NJ, Strikas RA. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55(RR-10): 1-42.
67. Davis MM, Taubert K, Benin AL, Brown DW, Mensah GA, Baddour LM, Dunbar S, Krumholz HM; American Heart Association; American College of Cardiology; American Association of Cardiovascular and Pulmonary Rehabilitation; American Association of Critical Care Nurses; American Association of Heart Failure Nurses; American Diabetes Association; Association of Black Cardiologists, Inc; Heart Failure Society of America; Preventive Cardiovascular Nurses Association; American Academy of Nurse Practitioners; Centers for Disease Control and Prevention and the Advisory Committee on Immunization. Influenza vaccination as secondary prevention for cardiovascular disease: A science advisory from the American Heart Association/American College of Cardiology. Circulation. 2006;114:1549-1553. (Pubitemid 44527011)
68. Piconi S, Trabattoni D, Luraghi C, Perilli E, Borelli M, Pacei M, Riz-zardini G, Lattuada A, Bray DH, Catalano M, Sparaco A, Clerici M. Treatment of periodontal disease results in improvements in endothelial dysfunction and reduction of the carotid intima-media thickness. FASEB J. 2009;23:1196-1204.
69. Grayston JT. Antibiotic treatment of atherosclerotic cardiovascular disease. Circulation. 2003;107:1228-1230.
70. Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestein B, Giugliano RP, Cairns R, Skene AM; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med. 2005;352:1646-1654.
71. Grayston JT, Kronmal RA, Jackson LA, Parisi AF, Muhlestein JB, Cohen JD, Rogers WJ, Crouse JR, Borrowdale SL, Schron E, Knirsch C; ACES Investigators. Azithromycin for the secondary prevention of coronary events. N Engl J Med. 2005;352:1637-1645.